Tag Archives: Vascepa

Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

A drug’s EU launch seldom becomes more important than its U.S. rollout from a market opportunity perspective, but that’s exactly what’s happening to Amarin’s fish oil-derived heart drug Vascepa. Amarin has started prepping sales reps in Germany for the planned launch of Vascepa—to be sold under the brand Vazkepa in Europe—before the end of September,… Read More »

FDA panel unanimously backs expanding use of Amarin’s heart drug Vascepa

(Reuters) – A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc’s fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease. The panel on Thursday voted 16-0 in favor of expanding approval, potentially opening up a… Read More »